Article
Developing peptide-based inhibitors of amylin aggregation as a novel treatment for type 2 diabetes
2017-01-01
Abstract excerpt
Human islet amyloid polypeptide (hIAPP), also known as amylin, is the main constituent of the amyloid deposits present in approximately 95% of people with type 2 diabetes. Amylin aggregates into oligo-/polymeric sheet structures which are considered to be cytotoxic to pancreatic -cells. Inhibiting the early stages of amylin aggregation could provide a potential therapeutic strategy for the treatment of type 2 diab...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8e35cf2d-b3b7-563b-88b2-82207c8285e4
- DOI
- 10.17635/lancaster/thesis/149
